Seeking Alpha: Expense Control Is Good, But Merck's Catalysts Lie Elsewhere

Biopharma investing a big exercise in "hurry up … and wait"; there's a lot of space to fill between the major pivotal clinical data releases and FDA decisions, and while earnings reports are not trivial, they don't often impact the long-term story all that much. In other words, if you liked Merck (MRK) before, there's no reason not to now (and vice versa).

Please read more here:
Expense Control Is Good, But Merck's Catalysts Lie Elsewhere